Logo

People in the News: Jerry Randall, Simon Sturge, Annie Cheng, Klaus Geise, Jorg Kaufmann

Nov 21, 2013
Premium

Silence Therapeutics said that its executive chairman Jerry Randall has stepped down from his position at the company.

He was replaced with Simon Sturge, formerly a non-executive director of the company. Sturge, however, will serve as chairman in a non-executive capacity, Silence said.

Additionally, Annie Cheng has been promoted from director of corporate development to chief operating officer.

Klaus Giese has also retired as Silence's CSO, and will be replaced by Jorg Kaufmann. Both Geise and Kaufmann were co-founders of Silence predecessor company Atugen.

Filed under

Gene Editing, Gene Silencing, & CRISPR
RNAi
Silence
Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.